| 000 | 01787 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516105124.0 | ||
| 264 | 0 | _c20130906 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1476-5594 | ||
| 024 | 7 |
_a10.1038/onc.2012.338 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSully, K | |
| 245 | 0 | 0 |
_aThe mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling. _h[electronic resource] |
| 260 |
_bOncogene _cJul 2013 |
||
| 300 |
_a3254-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAgammaglobulinaemia Tyrosine Kinase |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aCell Transformation, Neoplastic _xdrug effects |
| 650 | 0 | 4 |
_aEpidermis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aImmunoprecipitation |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xpharmacology |
| 650 | 0 | 4 |
_aIsoenzymes _xmetabolism |
| 650 | 0 | 4 |
_aKeratinocytes _xdrug effects |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xmetabolism |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aSirolimus _xpharmacology |
| 650 | 0 | 4 | _aSkin |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aUltraviolet Rays |
| 700 | 1 | _aAkinduro, O | |
| 700 | 1 | _aPhilpott, M P | |
| 700 | 1 | _aNaeem, A S | |
| 700 | 1 | _aHarwood, C A | |
| 700 | 1 | _aReeve, V E | |
| 700 | 1 | _aO'Shaughnessy, R F | |
| 700 | 1 | _aByrne, C | |
| 773 | 0 |
_tOncogene _gvol. 32 _gno. 27 _gp. 3254-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/onc.2012.338 _zAvailable from publisher's website |
| 999 |
_c22022427 _d22022427 |
||